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Original Basic Science Report
Recombinant Human Proteoglycan-4 Mediates 
Interleukin-6 Response in Both Human and 
Mouse Endothelial Cells Induced Into a  
Sepsis Phenotype
Holly A. Richendrfer, PhD1,2; Mitchell M. Levy, MD3; Khaled A. Elsaid, PharmD, PhD4;  
Tannin A. Schmidt, PhD5; Ling Zhang, MD1,2; Ralph Cabezas, BS1,2; Gregory D. Jay, MD, PhD1,2
Objectives: Sepsis is a leading cause of death in the United States. 
Putative targets to prevent systemic inflammatory response syndrome 
include antagonism of toll-like receptors 2 and 4 and CD44 receptors 
in vascular endothelial cells. Proteoglycan-4 is a mucinous glycopro-
tein that interacts with CD44 and toll-like receptor 4 resulting in a 
blockade of the NOD-like receptor pyrin domain-containing-3 path-
way.   We hypothesized that endothelial cells induced into a sepsis 
phenotype would have less interleukin-6 expression after recombi-
nant human proteoglycan 4 treatment in vitro.
Design: Enzyme-linked immunosorbent assay and reverse transcrip-
tase-quantitative polymerase chain reaction to measure interleukin-6 
protein and gene expression.
Setting: Research laboratory.
Subjects: Human umbilical vascular endothelial cells, human lung 
microvascular endothelial cells, and transgenic mouse (wild type) 
(Cd44+/+/Prg4+/+), Cd44–/– (Cd44tm1HbgPrg4+/+), Prg4GT/GT (Cd44+/+ 
Prg4tm2Mawa/J), and double knockout (Cd44tm1Hbg Prg4tm2Mawa/J) lung 
microvascular endothelial cells.
Interventions: Cells were treated with 100 or 250 ng/mL lipopoly-
saccharide-Escherichia coli K12 and subsequently treated with 
recombinant human proteoglycan 4 after 30 minutes. Interleukin-6 
levels in conditioned media were measured via enzyme-linked immu-
nosorbent assay and gene expression was measured via reverse 
transcriptase-quantitative polymerase chain reaction with ΔΔ–Ct 
analysis. Additionally, human umbilical vascular endothelial cells and 
human lung microvascular endothelial cells were treated with 1:10 
diluted plasma from 15 patients with sepsis in culture media. After 30 
minutes, either 50 or 100 µg/mL recombinant human proteoglycan 
4 was administered. Interleukin-6 protein and gene expression were 
assayed. Proteoglycan 4 levels were also compared between control 
and sepsis patient plasma.
Measurements and Main Results:  Human umbilical vascular endothelial 
cell, human lung microvascular endothelial cell, and mouse lung micro-
vascular endothelial cell treated with lipopolysaccharide had significantly 
increased interleukin-6 protein compared with controls. Recombinant 
human proteoglycan-4 significantly reduced interleukin-6 in human and 
mouse endothelial cells. Interleukin-6 gene expression was significantly 
increased after lipopolysaccharide treatment compared with controls. 
This response was reversed by 50 or 100 µg/mL recombinant human 
proteoglycan-4 in 80% of sepsis samples in human umbilical vascular 
endothelial cells and in 60–73% in human lung microvascular endothelial 
cells. In Cd44–/– genotypes of the mouse lung microvascular endothelial 
cells, recombinant human proteoglycan-4 significantly reduced interleu-
kin-6 protein levels after lipopolysaccharide treatment, indicating that 
Cd44 is not needed for recombinant human proteoglycan-4 to have an 
effect in a toll-like receptor 4 agonist inflammation model. Patient sepsis 
samples had higher plasma levels of native proteoglycan-4 than controls.
Interpretation and Conclusions: Recombinant human proteoglycan-4 
is a potential adjunct therapy for sepsis patients and warrants future 
in vivo model studies.
Key Words: CD44; cytokines; inflammation; proteoglycan-4; sepsis; 
toll-like receptors
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Sepsis is the body’s immune response to infection in major organs including the lung, urinary tract, blood, and skin struc-tures. More than 1.5 million people are diagnosed with sepsis 
in the United States every year and roughly 250,000 of those patients 
die due to multiple organ failure with a mortality rate around 33% 
(1). Antibiotics treat the initiating cause of sepsis but effective treat-
ments intended to blunt immune cell dysfunction are needed.
The body’s immune response during sepsis is extensive and 
includes the up-regulation of pro-inflammatory cytokines, cas-
pases, C-reactive protein, procalcitonin, and transcription factors 
(2, 3). One of the commonly used biomarkers in sepsis is the cyto-
kine interleukin (IL)-6, which is thought to be indicative of the most 
severe cases of sepsis and is upregulated in inflammatory cellular 
pathways (4). IL-6 is a glycoprotein that is released from many dif-
ferent cell types during the immune reaction in response to patho-
gen-associated molecular patterns or damage-associated molecular 
patterns (5–8). Because it is noted as a severe sepsis biomarker (4, 
8), we chose to focus on the IL-6 response in the current study. At 
present, there is still no effective treatment that is able to target and 
counteract the intense immune response during sepsis, making the 
condition difficult to treat and stabilize (9). Previously the toll-like 
receptor (TLR)-4 antagonist resatorvid Tak242, a cyclohexene deriv-
ative, showed promise in a phase 2 trial (NCT00143611) in patients 
with acute sepsis but was unable to advance to phase 3 due to iatro-
genic methemoglobinemia caused by this small molecule (10).
Lubricin (proteoglycan-4 [PRG4]; genebank number NM_005807) 
is a mucin-like 224 kDa glycoprotein originally found as a lubricat-
ing substance within the synovial fluid of diarthrodial joints (11–15). 
More recently, it has been found in other tissues including lung, liver, 
brain, heart, bladder, bone, eye, uterus, cervix, and prostate indicat-
ing that it serves a multifunctional role (16–18). Lubricin has recently 
been implicated as an anti-inflammatory mediator in innate immu-
nity pathways (19–21), and CD44 (21–23) has been conceptualized 
to play a role in its entry into the cytoplasm thereby pointing to its 
role as a potential adjunct treatment in sepsis. Full-length recombi-
nant human PRG4 (rhPRG4) has been used in limited clinical trials 
in xerophthalmia and no adverse effects were recorded (24, 25).
Lipopolysaccharide, a potent agonist of the TLRs, was used in this 
work to recapitulate inflammatory triggers in vitro in endothelial cells 
that are observed in sepsis (26). We used both lipopolysaccharide and 
plasma from culture-negative and culture-positive sepsis patients to 
initiate a strong IL-6 response in human umbilical vascular endothe-
lial cells (HUVECs) and human lung microvascular endothelial cells 
(HLMVECs). Lipopolysaccharide was also used to treat transgenic 
mouse lung microvascular endothelial cells (MLMVEC) that were 
Cd44 sufficient or null. After lipopolysaccharide or patient plasma 
treatment, cell culture samples were treated with rhPRG4 in order 
to determine if IL-6 gene expression and protein levels were altered. 
The results of the current study indicate that rhPRG4 is a potential 
therapeutic that can be used to reverse the inflammatory response 
commonly seen in sepsis. Additionally, using transgenic MLMVECs, 
we show that rhPRG4 reduced IL-6 levels in both the presence and 
absence of the CD44 receptor and endogenous Prg4, indicating that 
CD44 may not be required in facilitating anti-inflammatory activity 
in these cells, especially in regard to TLR4 ligands. Lastly, PRG4 levels 
in sepsis patient plasma were assayed and compared with controls.
MATERIALS AND METHODS
Patient Samples
Patient plasma samples were obtained from Sepsis, [Extr- 
acorporeal Membrane Oxygentation], and [Acute Respiratory 
Distress Syndrome] biobank patients at Rhode Island Hospital 
under institutional review board protocol number 4116-16 and 
used to treat both HUVEC and HLMVEC. Patient demograph-
ics are shown in Supplementary Table 1 (Supplemental Digital 
Content 1, http://links.lww.com/CCX/A181).
Supplementary Materials and Methods (Supplemental Digital 
Content 2, http://links.lww.com/CCX/A182) provide additional 
information.
RESULTS
Enzyme-Linked Immunosorbent Assay IL-6 Protein 
Concentrations
HUVEC Culture—Lipopolysaccharide Treatment. Media from 
untreated control HUVECs had baseline levels of IL-6 protein of 
60.6 ± 1.0 pg/mL. Lipopolysaccharide treatment increased IL-6 
protein levels to 671.6 ± 53.39 pg/mL and was significantly higher 
from media untreated controls (p < 0.001) (Fig. 1A). IL-6 pro-
tein levels were significantly reduced by 5–150 µg/mL rhPRG4 
30 minutes after cells were treated with lipopolysaccharide. After 
lipopolysaccharide treatment, 5 µg/mL rhPRG4 reduced IL-6 
levels 32% to 459.9 ± 75.18 pg/mL (p < 0.01), 10 µg/mL rhPRG4 
reduced IL-6 levels 48% to 350.0 ± 22.0 pg/mL (p < 0.001), 25 
µg/mL rhPRG4 reduced IL-6 levels 88% to 77.7 ± 2.7 pg/mL 
(p < 0.001), 50 µg/mL rhPRG4 reduced IL-6 levels 91% to 63.84 
± 1.4 pg/mL (p < 0.001), 100 µg/mL rhPRG4 reduced IL-6 lev-
els 94% to 43.1 ± 1.1 pg/mL (p < 0.001), and 150 µg/mL rhPRG4 
reduced IL-6 levels 84% to 106.7 ± 15.8 pg/mL (p < 0.001). Cells 
treated with 25 or 150 µg/mL rhPRG4 alone had IL-6 levels that 
were not statistically different from untreated controls.
HLMVEC Culture—Lipopolysaccharide Treatment. Media 
from untreated control HLMVECs had baseline levels of IL-6 that 
were 277.9 ± 23.3 pg/mL. Lipopolysaccharide treatment increased 
IL-6 levels to 2,733.5 ± 85.4 pg/mL which was significantly higher 
compared with media from untreated controls (p < 0.001) (Fig. 
1B). After 30 minutes of lipopolysaccharide treatment 25, 50, and 
100 µg/mL rhPRG4 reduced IL-6 levels 79% to 566.8 ± 26.2, 87% 
to 349.0 ± 15.7, and 91% to 242.0 ± 10.3 pg/mL (p < 0.001 for all 
when compared with lipopolysaccharide). Cells treated with 150 
µg/mL rhPRG4 alone had IL-6 levels that were not significantly 
different from untreated controls.
HUVEC Culture—Patient Plasma Treatment. Eighty percent 
of sepsis patient plasma samples lowered IL-6 levels significantly 
following treatment with 50 µg/mL rhPRG4 (p < 0.05) (Fig. 2). As 
a positive control, lipopolysaccharide significantly increased IL-6 
levels to 385.7 ± 18.9 pg/mL from 13.6 ± 4.0 pg/mL media levels 
(p < 0.001) which was reversed with rhPRG4 treatment 97% to 
10.3 ± 2.5 pg/mL (p < 0.001) (data not shown). IL-6 values shown 
in Figure 2 were normalized by subtracting background levels of 
IL-6 from patient plasma.
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HLMVEC Culture—Patient Plasma Treatment. Sixty percent of 
sepsis patient plasma samples lowered IL-6 levels significantly follow-
ing treatment with 50 µg/mL rhPRG4 (p < 0.05) (Fig. 3). One sep-
sis patient plasma sample increased IL-6 following treatment with 
rhPRG4 treatment (p < 0.05, SEA 22). Lipopolysaccharide signifi-
cantly increased IL-6 protein levels from 96.3 ± 0.8 pg/mL in media 
controls to 1,318.0 ± 14.4 pg/mL (p < 0.001) which was decreased 
81% to 248.9 ± 11.7 pg/mL by 50 µg/mL rhPRG4 (p < 0.001) 
(data not shown). The IL-6 values shown in Figure 3 were normalized 
by subtracting background levels of IL-6 from patient plasma.
Lipopolysaccharide significantly increased IL-6 protein levels 
from 67.1 ± 2.6 pg/mL in media controls to 765.9 ± 12.6 pg/mL 
Figure 1. Concentration-dependent effect of recombinant human 
proteoglycan-4 (rhPRG4) on interleukin (IL)-6 production in 
lipopolysaccharide (LPS) stimulated human umbilical vascular endothelial 
cells (HUVEC) and human lung microvascular endothelial cells (HLMVEC). 
IL-6 protein concentrations measured via enzyme-linked immunosorbent 
assay after LPS followed by rhPRG4 treatment in HUVECs (A) and 
HLMVECs (B). Cells were treated with 250 ng/mL LPS for 30 min prior 
to rhPRG4 treatment for 23.5 hr. Data presented are mean + sem. *p < 
0.05, **p < 0.01, ***p < 0.001; all groups compared with LPS IL-6 values 
using analysis of variance with Dunnett post hoc comparison. NS = not 
significant.
Figure 2. Patient sepsis samples used in human umbilical vascular 
endothelial cell (HUVEC) culture. HUVEC culture treated with 100 µL of 
patient plasma and 900 µL media prior to 50 µg/mL recombinant human 
proteoglycan-4 (rhPRG4) treatment for 23.5 hr. Data from patient samples 
represent normalized interleukin (IL)-6 levels corrected for native levels 
of IL-6. Unpaired t tests within patient samples were used to determine 
significance. Data presented are mean + sem. *p < 0.05, **p < 0.01,  
***p < 0.001. Treatment with 250 ng/mL lipopolysaccharide served as a 
positive control and resulted in an IL-6 level of 385.7 ± 18.9 pg/mL (data 
not shown). NS = not significant, sea = Sepsis, [Extracorporeal Membrane 
Oxygentation], and [Acute Respiratory Distress Syndrome].
Figure 3. Patient sepsis samples used in human lung microvascular endothelial 
cell (HLMVEC) culture and treated with recombinant human proteoglycan-4 
(rhPRG4) at a low concentration. HLMVEC culture treated with 100 µL of 
patient plasma and 900 µL media prior to 50 µg/mL rhPRG4 treatment for 
23.5 hr. Data from patient samples represent normalized interleukin (IL)-6 levels 
corrected for native levels of IL-6. Unpaired t tests within patient samples were 
used to determine significance. Data presented are mean + sem. *p < 0.05, **p 
< 0.01, ***p < 0.001. Treatment with 250 ng/mL lipopolysaccharide served as 
a positive control and resulted in a IL-6 level of 1,318.0 ± 14.4 pg/mL (data 
not shown). NS = not significant, sea = Sepsis, [Extracorporeal Membrane 
Oxygentation], and [Acute Respiratory Distress Syndrome].
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(p < 0.001) which was decreased 75% to 193.4 ± 2.2 pg/mL by 
100 µg/mL rhPRG4 (p < 0.001) (data not shown). Seventy-
three percent of sepsis patient plasma samples lowered IL-6 lev-
els significantly following treatment with 100 µg/mL rhPRG4 
(p < 0.05) (Fig. 4). Twenty percent of sepsis patient plasma sam-
ples increased IL-6 levels significantly following treatment with 
100 µg/mL rhPRG4 (SEA 4, SEA 23, and SEA 24). The IL-6 values 
shown in Figure  4 were normalized by subtracting background 
levels of IL-6 from patient plasma.
MLMVEC Culture—Lipopolysaccharide Treatment. In wild 
type MLMVECs (Cd44+/+ Prg4+/+), lipopolysaccharide significantly 
increased IL-6 protein levels to 307.5 ± 23.7 pg/mL compared with 
media controls at 12.8 ± 5.3 pg/mL (p < 0.001) (Fig. 5A). However, 
all groups co-treated with both lipopolysaccharide and rhPRG4 
had significantly reduced IL-6 levels compared with the lipopoly-
saccharide control group. Compared with the lipopolysaccharide 
only treated cells, those subsequently treated with 50, 100, and 150 
µg/mL rhPRG4 had significantly reduced IL-6 levels that were low-
ered 26% to 227.3 ± 4.9 pg/mL (p < 0.01), 69% to 94.4 ± 23.3 pg/mL 
(p < 0.001), and 66% to 105.4 ± 10.1 pg/mL (p < 0.001).
In MLMVECs that were null for Cd44 (Cd44tm1Hbg Prg4+/+), 
lipopolysaccharide treatment significantly increased IL-6 pro-
tein levels to 145.1 ± 15.1 pg/mL compared with media controls 
measured at 2.3 ± 0.8 pg/mL (p < 0.001) (Fig. 5B). There was no 
change in IL-6 in cells treated with lipopolysaccharide and then 
subsequently treated with 50 µg/mL rhPRG4. However, compared 
with the lipopolysaccharide only group, cells subsequently treated 
with 100 and 150 µg/mL rhPRG4 had significantly reduced IL-6 
levels that were lowered 62% to 55.4 ± 16.1 pg/mL (p < 0.001) and 
58% to 60.9 ± 17.2 pg/mL (p < 0.01).
MLMVECs that were null for Prg4 (Cd44+/+ Prg4tm2Mawa/J) and 
treated with lipopolysaccharide had significantly increased IL-6 
levels measured at 237.0 ± 4.2 pg/mL compared with media con-
trols at 8.5 ± 3.1 pg/mL (p < 0.001) (Fig. 5C). Cells treated with 
lipopolysaccharide and then subsequently treated with 50 µg/mL 
rhPRG4 did not differ in IL-6 levels compared with lipopolysac-
charide treated cells. However, compared with the lipopolysaccha-
ride only group, cells subsequently treated with 100 and 150 µg/
mL rhPRG4 had significantly reduced IL-6 levels that were low-
ered 49% to 120.6 ± 3.5 pg/mL and 55% to 105.5 ± 11.3 pg/mL 
(p < 0.001 for both groups).
In MLMVECs that were double knockout (Cd44tm1Hbg 
Prg4tm2Mawa/J), cells treated with lipopolysaccharide had signifi-
cantly increased IL-6 levels measured at 167.5 ± 17.1 pg/mL in 
comparison to media controls at 2.5 ± 0.7 pg/mL (p < 0.001) 
(Fig. 5D). Cells treated with lipopolysaccharide and subsequently 
treated with 50, 100, and 150 µg/mL rhPRG4 had significantly 
reduced IL-6 compared with lipopolysaccharide only treated cells 
that were lowered 32% to 113.0 ± 3.1 pg/mL (p < 0.01), 78% to 36.2 
± 10.7 pg/mL (p < 0.001), and 80% to 33.5 ± 2.4 pg/mL (p < 0.001).
Supplementary Figure 1 (Supplemental Digital Content 3, http://
links.lww.com/CCX/A183; legend, Supplemental Digital Content 
7, http://links.lww.com/CCX/A187), Supplementary Figure 2 
(Supplemental Digital Content 4, http://links.lww.com/CCX/
A184; legend, Supplemental Digital 
Content 7, http://links.lww.com/
CCX/A187), Supplementary Figure 
3 (Supplemental Digital Content 
5, http://links.lww.com/CCX/
A185; legend, Supplemental Digital 
Content 7, http://links.lww.com/
CCX/A187), Supplementary Figure 
4 (Supplemental Digital Content 6, 
http://links.lww.com/CCX/A186; 
legend, Supplemental Digital Content 
7, http://links.lww.com/CCX/
A187), and Supplementary Results 
(Supplemental Digital Content 8, 
http://links.lww.com/CCX/A188) 
provide additional information.
DISCUSSION
The TLR family includes many 
members each playing interrelated 
roles in host defense mechanisms 
during the immune response (27). 
Lipopolysaccharide is a strong ago-
nist of the TLRs and upon binding, 
results in an inflammatory cascade 
within the cell, leading to the release 
of cytokines and chemokines, includ-
ing IL-6 (28, 29). The majority of the 
culture-positive clinical isolates used 
Figure 4. Patient sepsis samples used in human lung microvascular endothelial cell (HLMVEC) culture and 
treated with recombinant human proteoglycan-4 (rhPRG4) at a high concentration. HLMVEC culture treated 
with 100 µL of patient plasma and 900 µL media prior to 100 µg/mL rhPRG4 treatment for 23.5 hr. Data from 
patient samples represent normalized interleukin (IL)-6 levels corrected for native levels of IL-6. Unpaired t tests 
within patient samples were used to determine significance. Data presented are mean + sem. *p < 0.05,  
**p < 0.01, ***p < 0.001. Treatment with 250 ng/mL lipopolysaccharide served as a positive control and resulted 
in an IL-6 level of 765.9 ± 12.6 pg/mL (data not shown). NS = not significant, sea = Sepsis, [Extracorporeal 
Membrane Oxygentation], and [Acute Respiratory Distress Syndrome].
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in this study contained lipopolysaccharide by virtue of the pres-
ence of Escherichia coli. The glycoprotein IL-6 is released from 
many cell types, including endothelial cells (30), as a result of 
tissue injury or pathogen invasion. It is a ubiquitous biomarker 
of severe sepsis in both neonates and adults (4, 6–8, 31–35). 
Therefore, we chose to evaluate IL-6 protein and gene expression 
in the current study as a representation of a sepsis-like response by 
mouse and human endothelial cells. Endothelial cells were chosen 
because their function is highly affected during sepsis (36). Barrier 
function, signal transduction, vasoregulation, and blood coagula-
tion are all affected by endothelial cells due to their intimal loca-
tion in blood vessels (36). Dyscrasias in endothelial cells caused by 
sepsis plays a major role in blood vessel permeability, acidosis, and 
coagulopathy. Macrophages were not studied in this investigation 
as we have already shown that NOD-like receptor pyrin domain-
containing-3 (NLRP3) is inhibited by rhPRG4 in a human leuke-
mia monocytic cell line THP-1 cells (21).
The lipopolysaccharide used in the current study was the E. 
coli K12-ultrapure variety which only activates TLR4 receptors. 
Levels of IL-6 protein and gene expression significantly increased 
in HUVECs, HLMVECs, and MLMVECs after cells were treated 
with lipopolysaccharide in the cur-
rent study. Furthermore, the results 
of the current study show that even 
though lipopolysaccharide elicited a 
significant increase of IL-6 protein lev-
els and gene expression in HUVECs, 
HLMVECs, and MLMVECs these 
levels were reversed by rhPRG4 in a 
concentration-dependent manner. 
Although this study is the first of its 
kind to use endothelial cells treated 
with rhPRG4, the results indicate that 
rhPRG4 has strong anti-inflammatory 
properties consistent with similar 
studies in other cell types, pointing to 
an anti-inflammatory role of lubricin 
(19–23). These studies indicate that 
PRG4 has two biological mechanisms 
of action within the cell in order to 
counteract inflammation.
Both native human PRG4 (nhPRG4) 
and rhPRG4 were found to bind to and 
act as an antagonist to TLR2 and TLR4 
receptors in the human embryonic kid-
ney-293 reporter cell line which was 
verified using enzyme-linked immu-
nosorbent assay, flow cytometry, and 
immunoprecipitation (19). nhPRG4 
was also able to block activation of 
both TLR2 and TLR4 after the ago-
nists synthetic triacylated lipoprotein 
and lipopolysaccharide were used, fur-
ther supporting the role of PRG4 as an 
anti-inflammatory biologic (19). These 
results fall in line with the results of our 
current study in that rhPRG4 competes with lipopolysaccharide in 
a concentration-dependent manner in order to prevent and reverse 
inflammation because the addition of rhPRG4 in our experiments 
occurred “after” cells were exposed to lipopolysaccharide. In using 
MLMVECs that were null for Cd44, there remained a reduction in 
IL-6 following rhPRG4 treatment, indicating that its anti-inflam-
matory properties are not dependent on an interaction with CD44. 
Overall, endothelial cells that were Cd44 null (Cd44tm1HbgPrg4+/+ and 
Cd44tm1HbgPrg4GT/GT) showed a net lower level of IL-6 upon exposure 
to lipopolysaccharide indicating that animals sufficient for Cd44 may 
have greater inflammatory effects from an induced cellular sepsis 
response. We also observed in Figure 5 that rhPRG4 is more effective 
than the endothelial cell’s native Prg4 in lowering IL-6.
Inflammatory cascades within many cell types, including endo-
thelial cells, are also activated via activation of the CD44 receptor. If 
the inflammatory cascades are activated within the cell, the NLRP3 
inflammasome becomes activated and nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB) nuclear translocation 
occurs, both of which drive cytokine release from the cell (21, 22, 
37–40). Previous studies indicate that rhPRG4 blocks NF-κB translo-
cation and prevents activation of the NLRP3 inflammasome after it is 
Figure 5. Interleukin (IL)-6 levels from transgenic mouse lung microvascular endothelial cells after 
lipopolysaccharide (LPS) and recombinant human proteoglycan-4 (rhPRG4) treatments. IL-6 protein 
concentrations measured via enzyme-linked immunosorbent assay after 100 ng/mL LPS and rhPRG4 treatment 
in wild-type (Cd44+/+ Prg4+/+) (A), Cd44 null (Cd44tm1Hbg Prg4+/+) (B), Prg4 null (Cd44+/+ Prg4tm2Mawa/J) (C), and 
double knockout (DKO) (Cd44tm1Hbg Prg4tm2Mawa/J) (D). Cells were treated with LPS for 30 min prior to rhPRG4 
treatment for 23.5 hr. Data presented are mean + sem. *p < 0.05, **p < 0.01, ***p < 0.001; all groups compared 
with LPS IL-6 values using analysis of variance with Dunnett post hoc comparison. NS = not significant.
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internalized in the cell (22). The results from that study indicated that 
aside from the well-known agonist, hyaluronic acid, rhPRG4 is also a 
ligand for the CD44 receptor and binds with a higher affinity than HA 
(22). However, rhPRG4 still showed anti-inflammatory properties in 
endothelial cells null for Cd44. Therefore, it is possible that rhPRG4 
exerted its effects via a different mechanism, such as inactivation of 
TLR4 and possible cellular internalization via other receptor-medi-
ated and nonreceptor mediated pathways.
Based upon the results of the current study and previous stud-
ies, it appears that rhPRG4 may be useful as an adjunct therapeu-
tic for a variety of disorders with an immune reaction, including 
sepsis by either antagonizing TLR2 and TLR4, as was recently 
reviewed (41). Although a CD44 dependent mechanism in endo-
thelial cells was not observed, this cell surface receptor may still be 
involved in other immune cells such as macrophages (21). TLR2 
and TLR4 have been antagonized in the past in clinical studies 
using small molecules (10) which appeared promising but eluded 
translation. PRG4 is normally present in the serum in low levels 
as it is expressed by hepatocytes and many other organ systems 
(16–18, 42). In our study, sepsis patients showed higher overall 
PRG4 levels in plasma in comparison to control patients which 
indicate that PRG4 may act as an antagonist in the sepsis response 
in humans (Supplementary Results, Supplemental Digital Content 
8, http://links.lww.com/CCX/A188). However, there was no 
within-subject correlation between IL-6 and PRG4 levels in sepsis 
patient plasma which could be due to the timing of plasma collec-
tion and sepsis severity. In a mouse sepsis model, an organ-based 
proteomics study (43) indicated that both protein and transcript 
levels of Prg4 were upregulated in the liver suggesting it may act 
as an antagonist of the sepsis response in a murine model as well.
When endothelial cells were treated with plasma from septic patients, 
the results of IL-6 protein levels and gene expression (Supplementary 
Results, Supplemental Digital Content 8, http://links.lww.com/CCX/
A188) did not share the same magnitude of change as the results from 
cells treated with only lipopolysaccharide. This may have been due to 
our RNA collection timepoint at 24 hours post lipopolysaccharide and 
rhPRG4 treatment or due to the array of inflammatory factors in the 
septic plasma. Plasma from septic patients can contain either gram-
positive and negative bacterial components and a variety of cytokines. 
These components can further amplify inflammation as measured in 
our assays via interaction with tumor necrosis factor receptor, CD44, 
and other targets which may explain why rhPRG4 did not decrease 
IL-6 protein and gene expression in all cell samples treated with sep-
tic patient plasma (44–49). Furthermore, it is also possible that gene 
expression analysis should have been performed at an earlier time-
point than 24 hours post-treatment with patient plasma due to the 
latency between upregulated gene expression and subsequent protein 
release. For example, it has been reported that peak cytokine release 
occurs between 2 and 6 hours post lipopolysaccharide administration 
in macrophages and liver tissue (50–52). Unfortunately, due to limita-
tions on patient plasma availability, only one timepoint was used for 
both protein and RNA analysis in our study.
As far as limitations of our study, we believe this study is relevant 
to the early stages of sepsis that are lipopolysaccharide dependent. 
Sepsis is a complicated disease process that takes time to evolve; as it 
does, a biomolecule like PRG4 theoretically becomes less effective. 
Ongoing work on additional patient samples will be conducted in 
order to study endothelial cell gene expression at earlier sepsis time-
points post lipopolysaccharide and rhPRG4 treatment in vitro. We 
are presently also using an in vivo mouse model to test the effects of 
rhPRG4 in an lipopolysaccharide-induced sepsis model.
CONCLUSIONS
Based upon the data presented in the current study, innate 
immune cellular responses of IL-6 from HUVECs, HLMVECs, 
and MLMVECs can be reversed by treatment with rhPRG4. 
Therefore, we believe that rhPRG4 is deserving of additional study 
as a potential adjunct therapeutic for sepsis patients.
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